Navigation Links
Blood test predicts success of quitting smoking using the nicotine patch

A blood test may enable doctors to predict which smokers using the nicotine patch are likely to experience the least amount of cravings and have the highest probability of success in quitting cigarettes, according to the results of a study in the June issus of the Journal of Clinical Pharmacology and Therapeutics.

The blood test, which is a measure of the rate at which nicotine is metabolized, may eventually be performed non-invasively using saliva or urine samples. "The ultimate aim here is to distinguish smokers who are likely to benefit from a standard dose of nicotine patch from those who may need a higher dose patch or an alternative therapy in order to succeed in quitting," said lead researcher for the study, Caryn Lerman, PhD, Associate Director for Cancer Control and Population Science at the Abramson Cancer Center of the University of Pennsylvania, and Director of the University of Pennsylvania Transdisciplinary Tobacco Use Research Center.

When nicotine is metabolized ?or broken down in the body ?it turns to cotinine. Cotinine is then metabolized to 3-hydroxycotinine (3-HC) by an enzyme in the liver. This study measured the ratio of these two breakdown products of nicotine among 480 smokers. A high ratio meant rapid metabolism of nicotine, which was associated with higher amounts of craving and greater difficulty in quitting cigarettes using the nicotine patch.

The smokers who participated in the study quit smoking and started using either the patch or the nicotine nasal spray for eight weeks. Measurements of carbon monoxide levels in exhaled air identified those who were not smoking at the eight-week and six-month intervals following the quit date. Study participants also provided information on level of cravings for cigarettes one week after their quit date.

"Using the rate of nicotine metabolism, we were able to predict the level of cravings and the efficacy of the nicotine patch," said Lerman. "Similar results could no t be obtained for the nicotine spray, most likely because the subjects were able to compensate for rapid metabolism of nicotine by using the spray more often."

"If a prospective study replicates these results, we will be in a position to recommend this blood test to tailor the type and dose of nicotine replacement therapy for smokers who wish to quit," Lerman said.


'"/>

Source:University of Pennsylvania School of Medicine


Related biology news :

1. Placenta Is A Rich Source Of Blood Stem Cells
2. Infants With Rare Genetic Disease Saved by Cord Blood Stem Cells
3. White Blood Cell Waste Disposal System Plays Critical Regulatory Role
4. Mystery Blood Vessel Disorder Implicated In Mini Strokes
5. Infants with Rare Genetic Disease Saved By Cord Blood Stem Cells
6. Young Blood Revives Aging Muscles, Stanford Researchers Find
7. Stem Cells to Solve the Blood Shortage Problem?
8. Blood flow in brain takes a twist, affecting views of Alzheimers
9. Blood-compatible nanoscale materials possible using heparin
10. Blood transfusion-transmitted infections: A global perspective
11. Blood sugars manufacture limited by building blocks supply
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
(Date:6/22/2016)... 2016 Research and Markets has announced the ... to their offering. The ... $29.3 billion in 2013. The market is expected to grow at ... to 2020, increasing from $50.6 billion in 2015 to $96.6 billion ... the forecast period (2015 to 2020) are discussed. As well, new ...
(Date:6/22/2016)... ... June 21, 2016 , ... New light-based technologies that facilitate a “look inside” ... to enable both compact, wearable devices for point-of-care diagnostics as well as powerful new ... Recent work and visionary future directions are detailed in a new open-access article by ...
Breaking Biology Technology: